- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Fresenius SE & Co KGAA O.N. (FREG)
The Fresenius SE share price today is 39.490, view ETR FREG stock exchange data. Track the latest Fresenius SE share price with real-time updates on FREG stock performance including market cap, day range, 52-week range and dividend yield. Access FREG charts, earnings dates and analyst estimates to support your investment decisions.
39.490
-1.320(-3.23%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
39.160
40.825
52 wk Range
39.160
52.960
Earnings results expected tomorrow
1/3
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
39.16040.825
52 wk Range
39.16052.960
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.55%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.55%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
FREG Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
54.971
Upside
+39.20%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
12 Buy
2 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 54.971
(+39.20% Upside)
Earnings
Latest Release
24-02-2026
EPS / Forecast
0.78 / 0.91
Revenue / Forecast
5.88B / 5.86B
Compare FREG to Peers and Sector
Metrics to compare | FREG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFREGPeersSector | |
|---|---|---|---|---|
P/E Ratio | 15.0x | 19.9x | −0.5x | |
PEG Ratio | 0.09 | 0.54 | 0.00 | |
Price/Book | 1.2x | 1.7x | 2.6x | |
Price / LTM Sales | 1.0x | 1.9x | 3.3x | |
Upside (Analyst Target) | 39.6% | 29.4% | 47.1% | |
Fair Value Upside | Unlock | 32.3% | 6.2% | Unlock |
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Fresenius SE (FREG) Share Price Today?
The Fresenius SE share price today is 39.490.
What is the current Fresenius SE (FREG) share price and day range?
As of 05-05-2026, the Fresenius SE share price is 39.490, with a previous close of 40.810. The share price has ranged from 39.160 to 40.825 today, while the 52-week range spans from 39.160 to 52.960.
What Is the Fresenius SE Market Cap?
As of today, Fresenius SE market cap is 22.190B.
Does Fresenius SE Pay Dividends? What's The Current Dividend Yield?
The Fresenius SE dividend yield is 2.55%.
What Is the Fresenius SE (FREG) Share Price Target?
The average 12-month share price target for Fresenius SE is 54.971, with a high estimate of 58 and a low estimate of 48. 12 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +39.20% Upside potential.
What Is Fresenius SE's Earnings Per Share (TTM)?
The Fresenius SE EPS (TTM) is 2.240.
When Is the Next Fresenius SE Earnings Date?
Fresenius SE will release its next earnings report on 06-05-2026.
From a Technical Analysis Perspective, Is FREG a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Fresenius SE Trade On?
Fresenius SE is listed and trades on the Frankfurt Stock Exchange.
What Is the Stock Symbol for Fresenius SE?
The stock symbol for Fresenius SE is "FREG."
How Many Times Has Fresenius SE Stock Split?
Fresenius SE has split 4 times.
How Many Employees Does Fresenius SE Have?
Fresenius SE has 155186 employees.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.